TWIST1 GENE EXPRESSION AS A BIOMARKER FOR
PREDICTING PRIMARY DOXORUBICIN RESISTANCE
IN BREAST CANCER
Demir S1,10,*, Müslümanoğlu MH2, Müslümanoğlu M3, Başaran S4,
Çalay ZZ5, Aydıner A6, Vogt U7, Çakır T8, Kadıoğlu H9, Artan S1
*Corresponding Author: Selma Demir, Ph.D., Trakya University Faculty of Medicine, Department of
Medical Genetics, 22030 Iskender, Edirne, Turkey. Tel: +90(284)2357642/2330. Fax: +90(284)2357652.
E-mail: selmaulusal@trakya.edu.tr
page: 25
|
|
REFERENCES
1. World Health Organization (https://www.who.int/
cancer/prevention/diagnosis-screening/breast-cancer/
en/).
2. Filipova A, Seifrtova M, Mokry J, Dvorak J, Rezacova
M, Filip S, et al. Breast cancer and cancer stem
cells: A mini-review. Tumori. 2014; 100(4): 363-369.
3. Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L,
Frank M, et al. Adjuvant chemotherapeutic treatment
of 1650 patients with early breast cancer in routine
care in Germany: Data from the prospective TMK
cohort study. Breast Cancer. 2018; 25(3): 275-283.
4. Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L,
Locatelli M, Dalton M, et al. Cytotoxic drugs for
patients with breast cancer in the era of targeted treatment:
Back to the future? Ann Oncol. 2012; 23(3):
547-555.
5. Duffy MJ, O’Donovan N, McDermott E, Crown J.
Validated biomarkers: The key to precision treatment
in patients with breast cancer. Breast. 2016; 29: 192-
201.
6. Online Mendelian Inheritance in Man, OMIM®. Mc-
Kusick-Nathans Institute of Genetic Medicine, Johns
Hopkins University, Baltimore, MD, USA (https://
omim. org/).
7. Pajer P, Pecenka V, Karafiát V, Králová J, Horejsí
Z, Dvorák M. The twist gene is a common target of
retroviral integration and transcriptional deregulation
in experimental nephroblastoma. Oncogene. 2003;
22(5): 665-673.
8. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J,
Glackin C, et al. TWISTing stemness, inflammation
and proliferation of epithelial ovarian cancer cells
through MIR199A2/214. Oncogene. 2010; 29(24):
3545-353.
9. Tseng JC, Chen HF, Wu KJ. A twist tale of cancer metastasis
and tumor angiogenesis. Histol Histopathol.
2015; 30(11): 1283-1294.
10. Norozi F, Ahmadzadeh A, Shahjahani M, Sharabi S,
Saki N. Twist as a new prognostic marker in hematological
malignancies. Clin Transl Oncol. 2016; 18(2):
113-124.
11. Zhao Z, Rahman MA, Chen ZG, Shin DM. Multiple
biological functions of Twist1 in various cancers.
Oncotarget. 2017; 8(12): 20380-20393.
12. Qiao W, Jia Z, Liu H, Liu Q, Zhang T, Guo W, et al.
Prognostic and clinicopathological value of Twist
expression in breast cancer: A meta-analysis. PLoS
One. 2017; 12(10): e0186191-e0186202.
13. Andreotti PE, Linder D, Hartmann DM, Cree IA,
Pazzagli M, Bruckner HW. TCA-100 tumour chemosensitivity
assay: Differences in sensitivity between
cultured tumour cell lines and clinical studies. J Biolumin
Chemilumin. 1994; 9(6): 373-378.
14. Cree IA, Kurbacher CM, Untch M, Sutherland LA,
Hunter EM, Subedi AM, et al. Correlation of the
clinical response to chemotherapy in breast cancer
with ex vivo chemosensitivity. Anticancer Drugs.
1996; 7(6): 630-635.
15. Vogt U, Bielawski KP, Bosse U, Schlotter CM.
Breast tumour growth inhibition in vitro through the
combination of cyclophosphamide/metotrexate/5-
fluorouracil, epirubicin/cyclophosphamide, epirubicin/
paclitaxel, and epirubicin/docetaxel with the
bisphosphonates ibandronate and zoledronic acid.
Oncol Rep. 2004; 12(5): 1109-1114.
16. Kurbacher CM, Cree IA. Chemosensitivity testing
using microplate adenosine triphosphate-based luminescence
measurements. Methods Mol Med. 2005;
110: 101-120.
17. Livak KJ, Schmittgen TD. Analysis of relative gene
expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 2001;
25(4): 402-408.
18. Zelnak A. Overcoming taxane and anthracycline resistance.
Breast J. 2010; 16(3): 309-312.
19. Hofmann D, Nitz U, Gluz O, Kates RE, Schin-koethe
T, Staib T, et al. WSG ADAPT – adjuvant dynamic
marker-adjusted personalized therapy trial optimizing
risk assessment and therapy response prediction in
early breast cancer: Study protocol for a prospective,
multi-center, controlled, non-blinded, randomized,
investigator initiated phase II/III trial. Trials. 2013;
14: 261. doi: 10.1186/1745- 6215-14-261.
20. Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard
L. Evaluation of the cytotoxicity of the Bithionolcisplatin
combination in a panel of human ovarian
cancer cell lines. BMC Cancer. 2017; 17(1): 49.
21. Smith SC, Baras AS, Lee JK, Theodorescu D. The
COXEN principle: Translating signatures of in vitro
chemosensitivity into tools for clinical outcome prediction
and drug discovery in cancer. Cancer Res.
2010; 70(5): 1753-1758.
22. Wang LF, Yin HT, Qian XP, Wei J, Zhao Y, Yu LX, et
al. Beta-Tubulin III mRNA expression and docetaxel
sensitivity in non-small cell lung cancer. Clin Invest
Med. 2009; 32(6): E278-E284.
23. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky
S, Sartorelli V, Kedes L, et al. Twist is a potential
oncogene that inhibits apoptosis. Genes Dev. 1999;
13(17): 2207-2217.
24. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa
S, Kuntzen C, et al. Upregulation of Twist-1 by NFkappaB
blocks cytotoxicity induced by chemotherapeutic
drugs. Mol Cell Biol. 2007; 27(11): 3920-3935.
25. Wang L, Tan RZ, Zhang ZX, Yin R, Zhang YL, Cui
WJ, et al. Association between Twist and multidrug
resistance gene-associated proteins in Taxol®-resistantMCF-
7 cells and a 293 cell model of Twist overexpression.
Oncol Lett. 2018; 15(1): 1058-1066.
26. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F,
et al. Twist1-mediated adriamycin-induced epithelialmesenchymal
transition relates to multidrug resistance
and invasive potential in breast cancer cells.
Clin Cancer Res. 2009; 15(8): 2657-2665.
27. Saxena M, Stephens MA, Pathak H, Rangarajan A.
Transcription factors that mediate epithelial-mesenchymal
transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2011;
2: e179-e191.
28. Hillen F, Griffioen AW. Tumour vascularization:
Sprouting angiogenesis and beyond. Cancer Metastasis
Rev. 2007; 26(3-4): 489-502
29. Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin
C, De Backer O, et al. TMEM45A is essential for
hypoxia-induced chemoresistance in breast and liver
cancer cells. BMC Cancer. 2012; 12: 391-407.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
